Emami S, Chastre E, Bodéré H, Gespach C, Bataille D, Rosselin G
Peptides. 1986;7 Suppl 1:121-7. doi: 10.1016/0196-9781(86)90174-9.
Three separate sets of receptors sensitive to VIP, GIP and pancreatic/entero-glucagons, have been characterized in HGT-1 cells. The order of relative potencies of VIP receptor agonists was VIP greater than rh GRF-43, rh GRF-29 greater than PHI greater than hp GRF-40, secretin. G-37 was about 4 times less potent than G-29 in HGT-1 cells (G-29 greater than G-37), whereas it was about 20 times more potent than G-29 in rat fundic glands (G-37 greater than G-29). Adenylate cyclase in HGT-1 cells was stimulated by VIP, G-29, G-37 and GIP, over a concentration from 3.16 X 10(-9) to 3.16 X 10(-7) M GIP. The experimental data: (1) support the enterogastrone activity of GIP, via adenylate cyclase activation and somatostatin release by gastric D cells; (2) demonstrate that HGT-1 cells originating from a human fundic tumor are sensitive to the glucagon-like peptides G-29 and -37, as rat fundic glands; (3) indicate that the pharmacological properties of the VIP receptor in this human gastric cell line are similar to those characterized in normal human gastric glands.
在HGT-1细胞中已鉴定出三组分别对血管活性肠肽（VIP）、胃抑肽（GIP）和胰高血糖素样肽/肠高血糖素敏感的受体。VIP受体激动剂的相对效价顺序为：VIP＞重组人生长激素释放因子（rh GRF-43），重组人生长激素释放因子（rh GRF-29）＞胰高血糖素样免疫活性肽（PHI）＞人胰高血糖素样肽（hp GRF-40），促胰液素。在HGT-1细胞中，G-37的效价比G-29低约4倍（G-29＞G-37），而在大鼠胃底腺中，其效价比G-29高约20倍（G-37＞G-29）。在3.16×10⁻⁹至3.16×10⁻⁷M的GIP浓度范围内，HGT-1细胞中的腺苷酸环化酶受到VIP、G-29、G-37和GIP的刺激。实验数据：（1）通过胃D细胞激活腺苷酸环化酶和释放生长抑素，支持GIP的肠抑胃素活性；（2）证明源自人胃底肿瘤的HGT-1细胞与大鼠胃底腺一样，对胰高血糖素样肽G-29和G-37敏感；（3）表明该人胃细胞系中VIP受体的药理学特性与正常人胃腺中所鉴定的特性相似。
